🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🏆Big congratulations to Memorial Sloan Kettering Cancer Center #radonc residents Dr Chris Jackson, MD, MS (PGY4) and Dr Trisha Santos, MD, MS (PGY5) for their Conquer Cancer, the ASCO Foundation ASCO Annual Meeting Merit Awards for their #ASCO24 abstracts 🙌

Brandon Imber discussed the role of RDT in CNS lymphoma #MSKlymphomaCME - RDT is highly effective in CNS - RD-WBRT could be an interesting option for some patients - interesting data on imaging surrogates to evaluate cortical atrophy

Exciting p16+ oropharynx SCC (T0-T2, N0-N2C, 7th Ed) de-escalation data (hypoxia-response directed w/ FMISO PET) from Memorial Sloan Kettering Radiation Oncology Nancy Lee #hncsm team, now with 30 Gy to the primary too (no surgery). 2-year local failure of 4.2%, 99% OS! Note RF of 6.9% w/ 30 Gy elective neck

☢️🏙️ Learn about the Memorial Sloan Kettering Cancer Center #RadOnc residency program in beautiful NYC from our Chief Residents 🚕🥯🍕🖼️💃🪩🍽️🍣🌆 📅Monday, July 15 8–9 pm ET Register here: meetmsk.zoom.us/meeting/regist… 📅Monday, August 19, 8–9 pm ET Register here: meetmsk.zoom.us/meeting/regist…

Wild to think we are at the end of PGY3 of #radonc #residency Memorial Sloan Kettering Radiation Oncology Memorial Sloan Kettering Cancer Center An absolute honor to be on the journey with the best squad in town 🌆 @JeffMeng0 Nikhil Mankuzhy, MD Kaitlyn Lapen @AlexGoglia @RoshalP

☢️🏙️Learn about the Memorial Sloan Kettering Cancer Center #RadOnc residency program in beautiful NYC from our Chief Residents 🍽️🍣🌆🚕🖼️💃🧑‍🍳🎭👨‍🎤🍕 📅Monday, August 19 ⏰8–9 pm ET Register: meetmsk.zoom.us/meeting/regist… Matthew McMillan, MD Kate Hockemeyer Elisa Liu Alex Terry Shoshana Rosenzweig, MD Nikhil Mankuzhy, MD

WHAT A TIME TO BE ALIVE. 🦅 🇺🇸 #USABMNT #Paris2024 #Basketball

4Gy RT for limited-stage iNHLs #ASH24 Nikhil Mankuzhy, MD: - 157 pts: 45% FL, 46% MZL, 52% extranodal (mostly orbit) - ORR 95% (CR 77%) - 7 pts req'd addn'l 20-30 Gy - 5-yr local progression 18%, 5-yr PFS 58% Great data that supports our approach Rachel Rabinovitch Sarah Milgrom, MD. #lymsm

A new study by Chris Jackson, MD, MS & Dan Higginson identified the optimal dose of a type of targeted radiation used to treat people with cancer that has spread to their spine. These new recommendations minimize the risk of developing a complication during therapy known as

Congrats to the MSK Rad Onc Class of 2030! Looking forward to working with all of you!

Kevin Boehm Stefanie Gerstberger, MD PhD 2/3 Dr. Kevin Boehm, a postdoc fellow in computational oncology and resident physician in #radiationoncology, is applying machine learning to infer tumor subtypes and #genomic features from microscopic images. #AACR25 Learn more about his work: bit.ly/3YJBO9i

Very honored to have been invited to Memorial Sloan Kettering Cancer Center as Visiting Professor and Grand Round Speaker on bladder-preserving trimodality therapy! I had a great time visiting with friends, colleagues, and the amazing MSK residents. Memorial Sloan Kettering Radiation Oncology Bladder Cancer Advocacy Network Mass General Cancer Center

Response-adapted 4 Gy ▶️ 20-24 Gy in potentially curable iNHL. 281 pts, only 6% addn'l RT. 5-yr local progression 15%, 5-yr distant PD 22%. Randomized trial forthcoming. We have been doing this at CU Lymphoma Program (with Rachel Rabinovitch & Sarah Milgrom, MD) with success. #lymsm #18ICML

Amazing work Bea Fregonese presenting our initial results on financial toxicity and decision regret in #aya #hodgkinlymphoma survivors. There’s still time for patients to fill out the survey: bit.ly/3SLZ0ke

Standing room only for Nikhil Mankuzhy, MD oral on PET-response adapted 4 Gy for potentially curable indolent lymphomas! Great job pushing the frontier of RT! Memorial Sloan Kettering Radiation Oncology Memorial Sloan Kettering Cancer Center ILROG Team #18ICML

Beyond proud of our Memorial Sloan Kettering Radiation Oncology hematology research team! Exciting research at the forefront of all aspects of #18ICML!! Hopefully the Lago view makes up for all the hard work 😉 Memorial Sloan Kettering Cancer Center

🚨 The FDA has approved the immunotherapy drug #pembrolizumab (Keytruda®) to be given before and after surgery for patients with #headandneck squamous cell cancer (#HNSCC) in combination with standard therapy. Dr. Nancy Lee, a radiologist oncologist at MSK, helped design the

Congratulations to Iris Gibbs, MD, FASTRO; Helen Shih, MD, MS, MPH, FASTRO; & Joachim Yahalom, MD, FASTRO on their 2025 ASTRO Mentorship awards!! They will be recognized at #ASTRO25 in San Francisco. Stanford Radiation Oncology MassGeneral News Memorial Sloan Kettering Radiation Oncology ow.ly/A1cB50WlXIa

1/ Just published in IJROBP - The Red Journal: “Histological Classifier of Radiosensitivity to Spine SBRT.” doi.org/10.1016/j.ijro…

In an interview from #18ICML, Nikhil Mankuzhy, MD of Memorial Sloan Kettering Cancer Center provides insight into the efficacy of response-adapted very low-dose radiotherapy at a dose of 4 Gy for indolent #NonHodgkinLymphoma: 🎥 ow.ly/p8u350WjwPN #LYMsm #Lymphoma #RadOnc #HemOnc